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Rationale: Antiepileptic drugs are the mainstay of treatment for patients with epilepsy. Adherence to the pre-
scribed regimen is a major factor in achieving a reduced seizure burden, which can decrease morbidity andmor-
tality. Patientswith epilepsy oftentimes complain about difﬁcultywithmemory. Because little is known about the
relationship betweenmemory andmood and adherence, the purpose of this projectwas to determine the impact
of the confounding factors of memory and mood on antiepileptic drug adherence in patients with epilepsy.
Methods: One hundred adult patients with epilepsy were recruited from the outpatient neurology clinic for this
cross-sectional study. Patients who met the inclusion criteria completed measures of subjective memory (subset
of 6memory questions from theQOLIE-89) and objectivememory (Hopkins Verbal Learning Test—Revised), sub-
jective adherence (Morisky scale) and objective adherence (medication possession ratio), andmood (Neurological
Disorders Depression Inventory for Epilepsy). Reﬁll records from each patient's community pharmacy were used
to objectively assess adherence.Medication possession ratioswere calculated based on the antiepileptic drug reﬁll
records over the previous 6 months. Patients were considered adherent if their MPR was N80%.
Results:Women made up the majority of the sample (n = 59), and, on average, patients had been living with
epilepsy for nearly 20 years. Approximately 40% of the sample were on antiepileptic drugmonotherapy; most pa-
tients (N70%) took their antiepileptic drugs twice daily, and the mean number of total medications was 4.25 ±
2.98. Based on the objective measure of adherence, 35% of the patients were nonadherent. Patients self-reported
better adherence than what was objectively measured. Only the retention metric of the objective memory mea-
sure differentiated adherent patients from nonadherent patients. Patients in the adherent group had signiﬁcantly
lower depression scores (indicating better mood) compared with those in the nonadherent group (p = 0.04).
Conclusions: Objective memory measures were not robustly correlated with adherence. However, we observed
that patients with higher depressed mood scores were more likely to be nonadherent. By targeting patients
with epilepsy and comorbid depression, practitioners may identify patients at greatest risk of nonadherence and
subsequent harm.© 2014 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy is a common neurological problem affecting 1%–2% of
the population. Antiepileptic drugs (AEDs) are the mainstay of treat-
ment for patients with epilepsy, and adherence to the prescribed
drug regimen is a major step in achieving a reduced seizure burden.
Faught and colleagues have shown that decreased AED adherence is
associated with more than a 3-fold increase in mortality [1]. Periods of
nonadherence in patients with epilepsy were also associated with sig-
niﬁcantly more emergency department visits, hospital admissions,College of Pharmacy, 500 West
13.injuries, and fractures. A comprehensive review on AED adherence has
recently been published [2].
As in patients with epilepsy, medication adherence is an important
determinant of reaching optimal outcomes in patients with chronic
conditions. Adherence studies have been done in patients with other
chronic diseases such as hypertension, heart disease, diabetes, arthritis,
chronic obstructive pulmonary disease, asthma, depression, osteoporo-
sis, and high cholesterol [3].
The medication possession ratio (MPR) is a measure of adherence
frequently utilized in the literature [1]. It is calculated by dividing the
number of days of medication supplied within the reﬁll interval by the
number of days in the reﬁll interval. The resulting value is typically be-
tween 0 and 1, with anMPR value N0.8 being thewidely accepted cutoff
indicative of adherence.
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tions is especially evident in the care of patientswith epilepsy in tertiary
care epilepsy centers. Despite verbal reports of adherence in most pa-
tients, in a small prospective project, six (54.5%) of 11 patients had a
baseline AED MPR b 0.8 (unpublished data). Based on the current liter-
ature, the full contributors to adherence are unclear. There is extensive
literature on memory dysfunction in patients with epilepsy, and recent
data indicate that patients with epilepsy have a higher than previously
detected level of concern with their memory [4]. An additional con-
founding factor is the interplay of mood with subjective and objective
measures in patients with epilepsy [5]. To date, no literature that
explores the relationship between these confounding factors and adher-
ence in patients with epilepsy exists. The purpose of this project was to
determine the impact of the confounding factors of memory and mood
on AED adherence in patients with epilepsy.
2. Materials and methods
One hundred patients were recruited from the Ohio State University
Wexner Medical Center's Comprehensive Epilepsy Program for this
cross-sectional study. Institutional review board approval was obtained
before any patients were recruited. Adult patients with epilepsy taking
at least oneAED for the prior 6months and capable of providing consent
and completing the surveys by themselves were recruited. The patients
were also required to get their monthly AED reﬁlls from a community
pharmacy.
Demographic and seizure activity data were gathered. As an incen-
tive, all 100 patients were entered into a random drawing for four $25
gift certiﬁcates to a local store. Patients completed a brief battery of
tests to assess memory (subjective and objective), mood, and self-
reported adherence during their regularly-scheduled clinic appointment.
2.1. Memory
Subjective memory was assessed by asking the six memory domain
questions from the validated Quality of Life in Epilepsy-89 questionnaire
(QOLIE-89) which is reported as a percentage, with a higher score
equating to better memory [6]. Objective memory was measured by the
Hopkins Verbal Learning Test — Revised (HVLT-R), a brief assessment of
recognition and recall for individuals 16 years and older. Recommended
by the Epilepsy Common Data Elements group [7], the HVLT-R has been
validated within populations with brain disorders such as Alzheimer's,
Parkinson's, and Huntington's diseases as a measure of verbal learning
and memory [8] and has been found to be independently predictive of
everyday instrumental activities of daily living, problem-solving, andpsy-
chomotor speed [9]. This test provides fourmeasures: total recall, delayed
recall, retention %, and recognition discrimination index. To determine if
patientswho report subjectivememory complaints had a corollary deﬁcit
on an objective measure of memory, we compared each patient's QOLIE-
89 subset score (subjective) with their HVLT-R score (objective). The
HVLT-R total recall score (0 to 36) was converted into a percentage
(HVLT-R %), and a difference score (subjective− objective) was calcu-
lated. A negative score reﬂects that the patient did better on the objec-
tive memory test than on the subjective memory test.
2.2. Mood
Moodwas assessed by theNeurological Disorders Depression Inven-
tory for Epilepsy (NDDI-E). This is a patient-answered six-item ques-
tionnaire that has been shown to be sensitive and speciﬁc in patients
with epilepsy [10]. Lower scores represent better mood.
2.3. Adherence
Self-reported adherence was assessed by using the 4-question
Morisky scale [11] and a visual analog scale (VAS). Morisky et al.developed a brief, easily understood, and valid scale to be administered
to patients in the clinical setting. Scores range from 0 to 4, with
4 depicting high and 0 depicting low medication-taking behavior. Pa-
tientswere categorized into three groups: low (score of 0 or 1),medium
(score of 2 or 3), and high (score of 4) scores. For the VAS, patients were
asked to mark on a line anchored by “nonadherent” and “completely
adherent” where they felt depicted their AED adherence. Their VAS
score was calculated as a percent, with higher scores denoting better
self-reported adherence. Patients were also given the opportunity to
identify barriers and facilitators of their AED adherence (with the option
to choose more than one response).
Each patient's community pharmacy provider was contacted to ob-
tain their AED reﬁll history records over the previous 6 months. This in-
formation was used to calculate each patient's AED MPR: the objective
measure of adherence. For those patients on AED polytherapy, an aver-
age MPR was calculated. Based on MPRs, patients were separated into
adherent (ADH) [MPR N 0.8] and nonadherent (non-ADH) [MPR b 0.8]
categories. Reﬁll histories were not gathered for non-AED medications.2.4. Statistical analysis
Categorical datawere subjected to chi-square analysis with between
group comparisons of continuous data analyzed with Student's t-tests.
Continuous variable correlations were measured using Pearson's corre-
lation, and between-group comparisons of correlation were calculated
using Fisher's method [12].3. Results
3.1. Demographics
A convenience sample of 100 patients was recruited. Their demo-
graphic information is summarized in Table 1. Women made up the
majority of the sample, and, on average, patients had been living with
epilepsy for nearly 20 years. Approximately 40% of the sample were
on AED monotherapy; most patients (N70%) took their AEDs twice
daily, and the mean number of total medications was just over four.
There were no demographic differences between the ADH patients
and the non-ADH patients.3.2. Adherence
Objective adherence data (individual MPR scores) are presented
in Fig. 1. Sixty-ﬁve patients had an MPR greater than or equal to
0.8 and, thus, were categorized as ADH. Patients' self-assessment of
medication adherence (subjective adherence) via the Morisky score
and VAS demonstrated that a majority of both the ADH patients
and the non-ADH patients put themselves in the “medium” or in the
“high” adherence category (Table 2). When examining correlations
between adherence measures, we correlated both the Morisky scores
(r = 0.25, p = 0.005) and the VAS scores (r = 0.2, p = 0.02) with
MPR. There was no difference in either subjective adherence score
between the ADH group and the non-ADH group nor was there a signif-
icant difference between the groups in correlation of subjective adher-
ence and Morisky (z = 0.003, NS) or VAS (z = 0.17, NS) scores.
When patients were asked to identify barriers to their adherence, a
majority of each group (N70%) reported no adherence barriers (Fig. 2).
Ten percent of the entire sample identiﬁed cost as a barrier, though
this was slightly higher (14.3%) in the non-ADH patients, possibly due
to more patients in the latter group having income b $30,000 (77%)
compared with the ADH group (54%). When patients were asked
to identify adherence facilitators, the most common responses were
“own routine” (59% of the sample) and a pillbox (52% of the sample)
(Fig. 3).
Table 2
Summary of adherence, memory, and mood assessments.
Possible range ADH (MPR ≥ 0.8)
n = 65
Non-ADH (MPR b 0.8)
n = 35
Adherence
Morisky score 0 to 4
(higher is better)
4 (high) = 49.2% 4 (high) = 40%
2–3 (med) = 50.8% 2–3 (med) = 57.1%
0–1 (low) = 0% 0–1 (low) = 2.9%
Visual analog
scale
0 to 100
(higher is better)
90.03 ± 11.02 86.86 ± 17.25
Memory
QOLIE-89
subset
0 to 100
(higher is better)
61.34 ± 20.90 57.82 ± 24.44
HVLT-R 0 to 36
(higher is better)
23.75 ± 5.29 24.14 ± 4.89
HVLT-R % 0 to 100
(higher is better)
65.98 ± 14.69 67.06 ± 13.58
Difference
scorea
−100 to 100 −4.64 ± 25.37 −9.24 ± 22.22
[58.5% had a
negative score]
[63% had a
negative score]
Mood
NDDI-E 6 to 24
(lower is better)
11.60 ± 3.36 13.17 ± 4.15b
MPR = medication possession ratio, QOLIE = quality of life in epilepsy, HVLT-R =
Hopkins Verbal Learning Test — Revised, NDDI-E = Neurological Disorders Depression
Inventory for Epilepsy.
a Calculated as QOLIE-89 subset score − HVLT-R % score. A negative score meant that
patients did better on the objective memory measure (HVLT-R %) than on the subjective
measure (QOLIE-89 subset).
b p = 0.04.
Table 1
Patient demographics.
ADH
(MPR ≥ 0.8)
n = 65
Non-ADH
(MPR b 0.8)
n = 35
Age (mean ± SD) 39.74 ± 15.14 37.50 ± 14.78
Gender (M:F) 41.5%:58.5% 40%:60%
Years since 1st seizure (mean ± SD) 18.10 ± 14.02 20.46 ± 16.19
Number of AEDs 1 = 43.1% 1 = 40.0%
2 = 40.0% 2 = 34.3%
3 = 15.4% 3 = 22.9%
4 = 1.5% 4 = 2.8%
Number of AED doses/day 1 = 7.7% 1 = 14.3%
2 = 73.8% 2 = 77.1%
3 = 16.9% 3 = 8.6%
4 = 1.6% 4 = 0%
Total number of medications (mean ± SD) 4.23 ± 2.86 4.29 ± 3.29
Patients with conditions beyond epilepsy
Yes 69.2% 48.6%
No 30.8% 51.4%
Education
Some HS 3.1% 2.8%
HS, no college 23.1% 31.4%
Some college 35.4% 25.7%
Bachelor degree 21.5% 31.4%
Graduate/postgraduate 16.9% 8.7%
Income
Under $10,000 24.6% 42.8%
$10,001–$30,000 29.2% 34.3%
$30,001–$50,000 29.2% 8.7%
N$50,000 15.4% 11.4%
Did not answer 1.6% 2.8%
People living at home 2.71 ± 1.39 3.26 ± 1.63
Taking antidepressants
Yes 23.1% 25.7%
No 64.6% 68.6%
Did not answer 12.3% 5.7%
Documented mood disorder
Yes 21.5% 17.1%
No 66.2% 68.6%
Did not answer 12.3% 5.7%
Patients with active patient portals
Yes 41.5% 31.4%
No 40.0% 45.7%
Did not answer 18.5% 22.9%
AED = antiepileptic drug, HS = high school.
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No differences existed between the ADH group and the non-ADH
group for either the subjective memory scale (QOLIE-89 subset) or the
objective measure (HVLT-R) (Table 2). Discrete differences in memory
functions were detected between the ADH group and the non-ADH0.0
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Non-ADH (n=35)
ADH (n=65)
Fig. 1. Individual MPR scores grouped by adherence category.group on one of the four measures of the HVLT-R. Retention T-scores
were signiﬁcantly lower in the non-ADH group (p = 0.03), and recogni-
tion discrimination index trended toward being lower in the non-ADH
group (p = 0.09) [data not shown]. In the overall group, neither subjec-
tive nor objective memory scores were correlated with MPR. However,
between-groups comparison of correlations demonstrated signiﬁcant
correlations of the subjective and objective scores within the ADH group
(z = 2.42, p = 0.02) that was lacking in the non-ADH group (Table 3).
When examining the relationship between the subjective scores
and the objective scores, both the ADH group and the non-ADH group
had a negative difference score (−4.64% and−9.24%, respectively). A
majority of patients in both groups did better on the objective memory
test (HVLT-R) than on the self-assessment memory measure. Fig. 4 is
a scatter plot of individual difference scores by adherence category,
showing little impact of adherence category on this measure.
3.4. Mood
Table 2 illustrates the NDDI-E scores for each adherence group. Pa-
tients in the ADH group had signiﬁcantly lowermood scores (indicating7.69
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Fig. 2. Self-identiﬁed adherence barriers.
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Fig. 3. Self-identiﬁed adherence facilitators.
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Depressive symptoms demonstrated a signiﬁcant negative correlation
with subjective memory scores (r =−0.52, p b 0.0001). No signiﬁcant
correlation was found between depressive symptoms and objective
scores (data not shown). No between-groups comparison of correlation
was signiﬁcant.
3.5. Seizure activity
Fig. 5 depicts the seizure activity for our sample. Nearly 40% of the pa-
tients reported having seizures in the last month, and roughly about the
same proportionwere seizure-free for the last year. For purposes of data
analyses, seizure activity was separated into 2 categories — (1) if it had
been more than 12 months since their last seizure, patients were classi-
ﬁed as “seizure-free” and (2) if their last seizure was within the last 12
months, they were classiﬁed as “not seizure-free”. Chi-square analysis
comparing seizure freedom with adherence captured a signiﬁcant
group-by-group interaction (p = 0.0003), with seizure-free patients
more likely to be in the ADH group.
4. Discussion
Our project's primary purpose was to determine the impact of the
confounding factors ofmemory andmood on AED adherence in patients
with epilepsy. One would expect patients with epilepsy who are
nonadherent to suffer frommemory difﬁculties (compared with the ad-
herent group) asmemory is a key factor for patients to take their chronic
medications. This was not the case in our study. Though we measured
memory both objectively and subjectively, to our surprise, only reten-
tion (a speciﬁc measure from the HVLT-R) was signiﬁcantly different
between the ADH group and the non-ADH group. This suggests that
memory may play only a small role in adherence. As is the case in
other conditions, the relationship between memory and adherence is
multifactorial and complex [13].
When examining more closely the impact of mood on AED adher-
ence, we found that the ADH patients were less depressed than those
in the non-ADH group. The observed relationship between mood and
adherence in our sample is consistentwith data very recently publishedTable 3
Correlation coefﬁcients between subjective memory and objective memory.
Correlation with
subjective memory
ADH
Pearson (r)
Non-ADH
Pearson (r)
Fisher z score p value
T-score −0.06 0.46 2.42 0.02
Delayed 0.37 0.04 1.52 0.06
Retention 0.12 0.1 0.11 NS
Discrimination 0.40 0.20 0.92 NS
NS = not signiﬁcant.by Ettinger and colleagues [14]. Among other measures, they assessed
mood (using the NDDI-E) and adherence (using MPRs) in a cross-
sectional study of 465 adult patients with epilepsy. They found that de-
pression was correlated with an increased risk of nonadherence. The
association between depression and poor adherence is not limited
to patients with epilepsy [15,16]. Proposed explanations include, but
are not limited to; a sense of hopelessness, decreased motivation, and
poor concentration [14]. It is more and more evident that mood plays
a major role in the lives of patients with epilepsy. Previous evidence
suggested its role in affecting quality of life more than seizures, and
our data show its role in adherence [17].
Our study showed that just over one-third (35%) of our patients
were not adherent to their AEDs. This distinction was based on our
chosen measure of objective adherence — their 6-month reﬁll history
(MPRs). Though these data are consistent with the literature where
nonadherence to AEDs has been shown to range from 30% to 50%, it is
not trivial as AED adherence inﬂuences morbidity and mortality [1]. As
there is no “gold standard” for measuring adherence, Lehmann et al.
suggest that “triangulation” of methods may increase the validity
and reliability [18]. Interestingly, when we “triangulated” our data by
usingmultiple methods of measuring adherence, we found a mismatch
between self-reported adherence and objective adherence. Many of
our patients overestimated how well they adhere to their medication
regimen. Although the objective and subjective adherence measures
demonstrated correlation in our overall sample, there was no differen-
tial correlation found between the ADH group and the non-ADH
group, thereby indicating that perception of adherence was not a chief
factor in determining a patient's adherence state. Though AED adher-
ence may be routinely discussed during patient visits, there remains a
signiﬁcant gap between objective adherence and subjective adherence.
Practitioners need to better understand this gap by differently querying16.92
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Fig. 5. Seizure activity by adherence category.
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beyond epilepsy [19].
As with the adherence data, when we compared the objective
and subjective memory data in our patient sample, a gap was dis-
covered. A majority of patients in both groups did better on the objec-
tive memory test (HVLT-R) than on the self-assessment memory
measure (QOLIE-89 subset), indicating that some patients who report
memory complaints do not have a corollary deﬁcit on an objective
memory measure. Correspondence of performance in objective mea-
sures of memory with self-reported deﬁcits is poor [20]. Though they
did not use the same measures, Witt and colleagues reported that
44 (60%) of their 73 patients reported self-perceived memory deﬁcits
and that only 26 (36%) patients had objective memory impairment.
Of note, they underscored the importance of factoring in mood when
assessing memory. Marino and collaborators have shown that subjec-
tive perception of AED cognitive effects is more related to mood than
to performance on objective neuropsychological tests [21].
Our study is notwithout limitations. They include, but are not limited
to, a cross-sectional study design, usage of single tools to assess subjec-
tive memory and objective memory, and a convenience sample of pa-
tients from one epilepsy center. We also recognize that obtaining reﬁll
records on our patients may not wholly indicate AED adherence [18].
5. Conclusion
Objective memory measures were not robustly correlated with ad-
herence. However, we observed that patients with higher depressed
mood scores were more likely to be nonadherent. By targeting patients
with epilepsy and comorbid depression, practitioners may identify pa-
tients at greatest risk of nonadherence and subsequent harm. Future
studies should include the evaluation of supplemental adherence mea-
sures, such as reminder systems implemented through e-mails via pa-
tient portals, text messages, or phone calls. A recent review shows
that eHealth interventions show promise [22].
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